Plasma assay promising for diagnosis of early Alzheimer disease

Plasma assay promising for diagnosis of early alzheimer disease

(HealthDay)—Plasma β-amyloid (Aβ)42/Aβ40 corresponds with amyloid positron emission tomography (PET) status, according to a study published online Aug. 1 in Neurology.

Suzanne E. Schindler, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues measured Aβ42/Aβ40 in plasma and (CSF) samples obtained from 158 mostly cognitively normal individuals within 18 months of an amyloid PET scan.

The researchers identified high correspondence for plasma Aβ42/Aβ40 with amyloid PET status (receiver operating characteristic area under the curve [AUC], 0.88) and CSF p-tau181/Aβ42 (AUC, 0.85). There was a very high correspondence for the combination of plasma Aβ42/Aβ40,…

Read more…